SCHEMBL198303

SCHEMBL198303

Clc1cccc2nccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 4/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 1/20 0.54
NR4A2 P43354 1/20 0.48
CYP1A2 P05177 2/20 0.39
HSD17B10 Q99714 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPK1 P28482 1/20 0.39
PARP1 P09874 2/20 0.37
AURKA O14965 1/20 0.37
DAPK3 O43293 1/20 0.37
JAK2 O60674 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL28257008 0.98 MAPT (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL11391 0.84 KDM4E (0.46) MAPTALDH1A1KDM4EMEN1KMT2A
Fluoroacetate SCHEMBL27808717 0.82 KMT2A (0.41) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL5720239 0.76 KDM4E (0.48) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL3069598 0.75 KDM4E (0.58) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL198192 0.73 KDM4E (0.43) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL23589560 0.72 NQO2 (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL31558290 0.72 NQO2 (0.52) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL2011252 0.71 KDM4E (0.54) MAPTALDH1A1KDM4EMEN1KMT2A
SCHEMBL7683014 0.71 KDM4E (0.54) MAPTALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN UNIV TAIPEI MEDICAL (TW) 2025-11-13 US disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
EP-4225749-A1 COMPOUNDS AND METHODS OF TREATING CANCERS Cullgen (Shanghai), Inc. (CN) 2023-08-16 EP disclosed
CN-116583509-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2023-08-11 CN disclosed
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-30 US disclosed
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN TAIPEI MEDICAL UNIVERSITY (TW) 2022-08-11 US disclosed
EP-3458444-B1 HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF UNIV TAIPEI MEDICAL (TW) 2022-06-22 EP disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 US disclosed
CN-101772508-A Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL CO 2010-07-07 CN disclosed
EP-2192124-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-06-02 EP disclosed
EP-2172470-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-04-07 EP disclosed
CN-1114506-A Heterobicyclic sulfonamide derivatives and sulfonate derivatives EISAI CO LTD (JP) 1996-01-03 CN disclosed
US-5424313-A Bibyclic heteroacrylpiperazine derivatives having psychotropic activity, and pharmaceutical compositions containing these derivatives DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1995-06-13 US disclosed
EP-0189612-B1 NEW PHARMACEUTICAL COMPOSITIONS HAVING A PSYCHOTROPIC ACTIVITY DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1992-11-04 EP disclosed
EP-0189612-A1 New pharmaceutical compositions having a psychotropic activity DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1986-08-06 EP disclosed
US-4585472-A PRE- AND POSTEMERGENCE HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1986-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 MAPT 4219/4885ALDH1A1 2648/4885KDM4E 1863/4885
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 MAPT 1124/4885ALDH1A1 1092/4885KDM4E 2705/4885
US-20250346563-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC5 MAPT 2336/4885ALDH1A1 1274/4885KDM4E 480/4885
US-20220251043-A1 HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN HDAC1, HDAC3, HDAC2 MAPT 2296/4885ALDH1A1 1178/4885KDM4E 424/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR MAPT 150/4885ALDH1A1 4757/4885KDM4E 3646/4885
US-11427544-B2 Histone deacetylase 6 inhibitors and use thereof HDAC1, HDAC11, HDAC7 MAPT 2320/4885ALDH1A1 509/4885KDM4E 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.